Stratos Wealth Advisors LLC Purchases 76 Shares of Axon Enterprise, Inc $AXON

Stratos Wealth Advisors LLC raised its position in Axon Enterprise, Inc (NASDAQ:AXON) by 12.1% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 706 shares of the biotechnology company’s stock after purchasing an additional 76 shares during the period. Stratos Wealth Advisors LLC’s holdings in Axon Enterprise were worth $585,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of AXON. Jennison Associates LLC increased its stake in Axon Enterprise by 23,203.7% in the first quarter. Jennison Associates LLC now owns 614,053 shares of the biotechnology company’s stock valued at $322,961,000 after purchasing an additional 611,418 shares in the last quarter. Nuveen LLC bought a new stake in Axon Enterprise in the first quarter valued at approximately $264,796,000. McElhenny Sheffield Capital Management LLC bought a new stake in Axon Enterprise in the second quarter valued at approximately $255,833,000. Westfield Capital Management Co. LP increased its stake in Axon Enterprise by 29.8% in the first quarter. Westfield Capital Management Co. LP now owns 927,801 shares of the biotechnology company’s stock valued at $487,977,000 after purchasing an additional 212,931 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in shares of Axon Enterprise by 2.2% during the first quarter. Vanguard Group Inc. now owns 8,632,008 shares of the biotechnology company’s stock worth $4,540,005,000 after acquiring an additional 185,571 shares in the last quarter. Institutional investors own 79.08% of the company’s stock.

Analyst Upgrades and Downgrades

AXON has been the subject of several research reports. Zacks Research downgraded shares of Axon Enterprise from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 2nd. Morgan Stanley set a $885.00 price objective on shares of Axon Enterprise and gave the stock an “overweight” rating in a research report on Friday, July 11th. JMP Securities reissued a “market outperform” rating and set a $825.00 price objective on shares of Axon Enterprise in a research report on Monday, September 29th. Wolfe Research initiated coverage on shares of Axon Enterprise in a research report on Monday, July 7th. They set an “outperform” rating for the company. Finally, Bank of America increased their price objective on shares of Axon Enterprise from $895.00 to $1,000.00 and gave the stock a “buy” rating in a research report on Wednesday, August 6th. Fourteen investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $841.64.

Axon Enterprise Stock Performance

Shares of AXON opened at $670.68 on Monday. Axon Enterprise, Inc has a 12 month low of $422.38 and a 12 month high of $885.91. The firm has a fifty day simple moving average of $739.44 and a 200 day simple moving average of $719.61. The stock has a market capitalization of $52.65 billion, a price-to-earnings ratio of 165.60, a PEG ratio of 26.04 and a beta of 1.41. The company has a current ratio of 2.95, a quick ratio of 2.71 and a debt-to-equity ratio of 0.63.

Axon Enterprise (NASDAQ:AXON) last announced its earnings results on Monday, August 4th. The biotechnology company reported $2.12 EPS for the quarter, topping the consensus estimate of $1.54 by $0.58. Axon Enterprise had a net margin of 13.64% and a return on equity of 6.80%. The business had revenue of $668.54 million during the quarter, compared to analysts’ expectations of $641.77 million. During the same quarter in the prior year, the company posted $1.20 earnings per share. The firm’s revenue was up 32.6% on a year-over-year basis. Axon Enterprise has set its FY 2025 guidance at EPS. Research analysts forecast that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

Insider Transactions at Axon Enterprise

In other Axon Enterprise news, President Joshua Isner sold 15,919 shares of the stock in a transaction on Friday, August 15th. The shares were sold at an average price of $746.26, for a total value of $11,879,712.94. Following the completion of the sale, the president owned 238,379 shares in the company, valued at $177,892,712.54. This trade represents a 6.26% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Brittany Bagley sold 5,000 shares of the stock in a transaction on Monday, September 29th. The shares were sold at an average price of $713.88, for a total transaction of $3,569,400.00. Following the completion of the sale, the chief financial officer owned 93,592 shares of the company’s stock, valued at approximately $66,813,456.96. This represents a 5.07% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 59,932 shares of company stock valued at $45,115,616. 5.70% of the stock is owned by company insiders.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.